All News

March 20, 2024

AbTherx Appoints Jessica Stark, PhD, as Scientific Advisor

Glycoimmunology expert and co-inventor of AbLec technology joins AbTherx to expand expertise around challenging drug targets Mountain View, Calif. – March 20, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Jessica Stark, PhD, as a scientific advisor. In her new role, Dr. […]

Read More »

March 13, 2024

AbTherx Partners with Single Cell Technology for First Antibody Discovery Campaigns

Partnership provides AbTherx and licensees of AbTherx’s Atlas™ Mice access to Single Cell Technology’s proprietary single B cell screening engine Mountain View and San Jose, Calif. – March 13, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies to enable and accelerate antibody discovery, and Single Cell Technology, Inc. (“Single Cell”), a biotechnology company […]

Read More »

March 7, 2024

AbTherx Appoints Janine Schuurman, PhD, as Scientific Advisor

Antibody expert and co-inventor of DuoBody®, HexaBody®, and HexElect® technologies joins AbTherx to drive expansion of the Atlas™ Mice platform Mountain View, Calif. – March 7, 2024 – AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Janine Schuurman, PhD, as a scientific advisor. In […]

Read More »

March 4, 2024

AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies

Atlas™ Mice can now be evaluated by pharmaceutical and biotech companies and accessed through a network of preferred service providers Mountain View, Calif. – March 4, 2024 – AbTherx, a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies. […]

Read More »

November 28, 2023

AbTherx Appoints David Meininger, PhD, MBA as Chief Business Officer

Biopharma executive with proven track record brings substantial strategy, business development, and licensing experience to AbTherx leadership team Mountain View, Calif. – November 28, 2023 – AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of David Meininger, PhD, MBA to the newly created position […]

Read More »

August 16, 2023

AbTherx Appoints Gavin Thurston, PhD, as Scientific Advisor

Former Regeneron Oncology Leader Joins AbTherx to Advance its Antibody Discovery Platform Mountain View, Calif. – August 16, 2023 – AbTherx, a privately held biotech company with innovative technologies that enable and accelerate antibody discovery, today announced the appointment of Gavin Thurston, PhD, as a scientific advisor. In his new role, Dr. Thurston will provide […]

Read More »

June 7, 2023

AbTherx Launches a Next-Generation Antibody Discovery Platform

The company brings together a proven team and novel technologies to increase efficiencies in antibody discovery Mountain View and San Diego, Calif. – June 7, 2023 – AbTherx, Inc., a privately held biotech company with novel technologies that accelerate antibody discovery, announced the launch of its next-generation human antibody discovery platform. AbTherx’s novel transgenic mouse […]

Read More »

June 7, 2023

AbTherx Announces License Agreement with Gilead

License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform Mountain View and San Diego, Calif. – June 7, 2023 – AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (Nasdaq: GILD). The […]

Read More »